AI assistant
GlaxoSmithKline PLC — Director's Dealing 2016
Oct 18, 2016
5262_dirs_2016-10-18_cc2b121a-78f6-469d-9e70-e6be89c3ad1b.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7607M
GlaxoSmithKline PLC
17 October 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Sir Andrew Witty
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 3.852 |
| £17.00 | 210.425 |
| £17.00 | 562.209 |
| £17.00 | 1288.273 |
| £17.00 | 3864.847 |
| £17.00 | 5283.681 |
| £17.00 | 5722.843 |
d)
Aggregated information
Aggregated volume Price
16,936.13
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
CEO Designate
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 711.971 |
| £17.00 | 1339.653 |
| £17.00 | 1373.598 |
| £17.00 | 2344.931 |
d)
Aggregated information
Aggregated volume Price
5,770.153
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 2267.631 |
| £17.00 | 2325.081 |
| £17.00 | 2518.157 |
d)
Aggregated information
Aggregated volume Price
7,110.869
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 1042.651 |
| £17.00 | 1069.072 |
| £17.00 | 1369.301 |
d)
Aggregated information
Aggregated volume Price
3,481.024
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines GSK
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 273.464 |
| £17.00 | 298.195 |
| £17.00 | 344.671 |
d)
Aggregated information
Aggregated volume Price
916.330
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 518.340 |
| £17.00 | 564.838 |
d)
Aggregated information
Aggregated volume Price
1,083.178
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S A Hussain
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 2105.069 |
| £17.00 | 2429.724 |
| £17.00 | 2738.614 |
d)
Aggregated information
Aggregated volume Price
7,273.407
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 748.492 |
| £17.00 | 850.396 |
| £17.00 | 992.738 |
d)
Aggregated information
Aggregated volume Price
2,591.626
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 1067.932 |
| £17.00 | 1133.866 |
| £17.00 | 1249.482 |
d)
Aggregated information
Aggregated volume Price
3,451.28
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
SVP, Communications & Government Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 509.321 |
| £17.00 | 656.026 |
| £17.00 | 718.885 |
d)
Aggregated information
Aggregated volume Price
1,884.232
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, Pharmaceuticals R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 2300.167 |
| £17.00 | 2358.444 |
| £17.00 | 2909.770 |
d)
Aggregated information
Aggregated volume Price
7,568.381
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £17.00 | 137.240 |
| £17.00 | 145.217 |
| £17.00 | 153.140 |
d)
Aggregated information
Aggregated volume Price
435.597
£17.00
e)
Date of the transaction
2016-10-13
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHVDLFFQBFBFBZ
//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'vvMb-B97mF_-0AygI38Ik6KCY_o5LE_DRj0w2NyiVq55EiiLOEVIRiqpGiEYJyXySilSMEgfFB6Slg_WHCo_kVqfiBXIOsxFngoT4vVT4Fk1:NPA9MEHJy_Umk9l2xWx39E__kQSS8mzUu61BSaNtHMRe8KIb0HK97WUd6ffQB3KqiszfdciazwEzHAOOjTfmm5sihQzhDaNsqe50paVwF9w1'}});//]]>